Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. (4th May 2017)

• Record Type: Journal Article
• Authors: Musella, Martina; Manic, Gwenola; De Maria, Ruggero; Vitale, Ilio; Sistigu, Antonella
• Is Part Of: Oncoimmunology. Volume 6:Number 5(2017)
• Publication Date: 2017-05-04
• Subjects: Anticancer therapy -- cancer stem cells -- IFNs -- immunotherapy -- tumor immunity; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2017.1314424
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: If there is a great new hope in the treatment of cancer, the immune system is it. Innate and adaptive immunity either promote or attenuate tumorigenesis and so can have opposing effects on the therapeutic outcome. Originally described as potent antivirals, Type-I interferons (IFNs) were quickly recognized as central coordinators of tumor-immune system interactions. Type-I-IFNs are produced by, and act on, both tumor and immune cells being either host-protecting or tumor-promoting. Here, we discuss Type-I-IFNs in infectious and cancer diseases highlighting their dichotomous role and raising the importance to deeply understand the underlying mechanisms so to reshape the way we can exploit Type-I-IFNs therapeutically.